There is no cure for<unk> . Supportive care is indicated for each patient based on their specific symptoms, and can include eye drops to manage the alacrima, pharmaceutical management of seizures, feeding therapy and physical therapy. Most potential treatment options for<unk>  are in the pre-clinical stages. These include enzyme replacement therapy, as well as ENGase inhibitors. Efforts are also underway to find small-molecule stabilizers for the mutant<unk>  protein variants as a potential means to overcome the N-glycanase deficiency.
NGLY1 deficiency
LRBA deficiency
WNT4 deficiency
PMM2 deficiency
Janus kinase 3 deficiency
ZC4H2 deficiency
CDKL5 deficiency disorder
DOCK8 deficiency